Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomised, Double-blind, Placebo- and Active Controlled, Single Dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 in Patients With Peripheral Neuropathic Pain

NCT04494815 is registered in ClinicalTrials.gov with Shanghai SIMR Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04494815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04494815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomised, Double-blind, Placebo- and Active Controlled, Single Dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 in Patients With Peripheral Neuropathic Pain
Lead sponsor
Shanghai SIMR Biotechnology Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
September 18, 2020
Completion date
July 31, 2022
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral neuropathic pain